MOUNTAIN VIEW, Calif., Feb. 3, 2016 /PRNewswire/ -- Based on its recent analysis of the biopharmaceutical contract manufacturing market, Frost & Sullivan recognizes Boehringer Ingelheim Biopharmaceuticals GmbH with the 2015 Global Frost & Sullivan Award for Competitive Strategy Innovation and Leadership. Boehringer Ingelheim's contract manufacturing arm, known under the brand name Boehringer Ingelheim BioXcellence™, has steadily evolved into a preferred outsourcing partner for the biopharmaceutical industry. The company's integrated, one-stop-shop approach has underpinned its position as a leader in the biopharmaceutical contract manufacturing space.
"Boehringer Ingelheim Biopharmaceuticals GmbH provides customers with high-quality, flexible production platforms and cost-efficient, optimized processes that reduce the time-to-market," said Frost & Sullivan Best Practices Analyst, Norma Vela. "Moreover, Boehringer Ingelheim BioXcellence™ offers customized manufacturing services that range from cell line development to sterile, aseptic fill and finish."
Not one to glory in past success, Boehringer Ingelheim Biopharmaceuticals GmbH continually invests in upstream and downstream processes and capabilities to meet the growing needs of global biopharmaceutical partners. For example, the company's new, fully disposable, multi-product manufacturing platforms complement its current high-volume stainless steel bioreactors. The benefits stemming from this innovation, including short start-up times, lower production costs, quick process transfers and greater scalability, have the potential to change mammalian cell-based manufacturing for small volume products.
Each such step that Boehringer Ingelheim takes in terms of technological advancement strictly adheres to international guidelines. In fact, the company's notable regulatory track record is widely valued, luring several new consumers to the Boehringer Ingelheim Biopharmaceuticals fold.
In addition to technical excellence, the company's growth policy revolves around strategic geographic expansions. Boehringer Ingelheim Biopharmaceuticals GmbH is the first biopharmaceutical contract manufacturing organization with a facility in China, a truly pioneering feat.
"Overall, the company's focus on building strong, transparent customer service relationships with partners from around the globe will reinforce its status in the market," noted Vela. "Its risk-sharing partnerships that support biopharmaceutical enterprises' competitive goals will help Boehringer Ingelheim BioXcellence™ preserve its position at the helm of the biomanufacturing contract manufacturing domain for a long time to come."
Each year, Frost & Sullivan presents this Award to the company whose competitive strategy has yielded significant gains in market share during the research period. Often, the recognized company has taken advantage of recent market changes that facilitate the introduction of novel methods of capturing and solidifying market presence. Alternatively, it may have executed an inventive strategy within the existing competitive landscape, empowering itself to overtake the competition. The company captures the attention of the competition, which quickly adjusts in order to protect its own market position. These innovations are expected to produce lasting, precedent-setting trends in the industry.
Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service, and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research.
About Boehringer Ingelheim Biopharmaceuticals GmbH
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales. As a pioneer in biopharmaceuticals with more than 35 years of experience the company has brought more than 25 biologic medicines to patients around the world together with its customers. Boehringer Ingelheim Biopharmaceuticals supplies the Boehringer Ingelheim in-house development pipeline and marketed products e.g. Metalyse®, Actilyse® and Praxbind® as well as the contract manufacturing business, known as Boehringer Ingelheim BioXcellence™. Boehringer Ingelheim Biopharmaceuticals operates four best in-class biopharmaceutical development and manufacturing facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China).
For more information visit www.bioxcellence.com
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion.
Contact:
Mireya Espinoza
P: 210. 247.3870
F: 210.348.1003
E: mireya.espinoza@frost.com
